The document provides guidance for creatives to design a leave behind leaflet for Advagraf, a once-daily immunosuppressant. It should highlight Advagraf's convenience as a once-daily dose to improve compliance over Prograf's twice-daily dosing. Creative concepts could include emphasizing the drug's benefits through a corporate ad, reminders of once-daily dosing, educational information for patients, or giveaways.